Gilead Sciences is responding to a World Health Organization report that its experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China.
Gilead said the findings were inconclusive because the study was terminated early.
According to the study, it did not help speed the recovery of COVID-19 patients, according to FT and Stat News. A summary of the report was initially shared by the WHO before it was taken down.
"We believe the post included inappropriate characterizations of the study. The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions," according to a Gilead statement.."As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."
Lesson/reminder from this: Don't believe China or their representative W.H.O.
I worked on Pandemic planning 2005-2007. China & W.H.O. were the 2 great liars even then.
Gilead said the findings were inconclusive because the study was terminated early.
According to the study, it did not help speed the recovery of COVID-19 patients, according to FT and Stat News. A summary of the report was initially shared by the WHO before it was taken down.
"We believe the post included inappropriate characterizations of the study. The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions," according to a Gilead statement.."As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."
Lesson/reminder from this: Don't believe China or their representative W.H.O.
I worked on Pandemic planning 2005-2007. China & W.H.O. were the 2 great liars even then.
